Publications
Detailed Information
Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jung-Eun | - |
dc.contributor.author | Lee, Soon-Tae | - |
dc.contributor.author | Im, Woo-Seok | - |
dc.contributor.author | Chu, Kon | - |
dc.contributor.author | Kim, Manho | - |
dc.date.accessioned | 2010-07-07T10:52:53Z | - |
dc.date.available | 2010-07-07T10:52:53Z | - |
dc.date.issued | 2008-10-22 | - |
dc.identifier.citation | Neurosci Lett. 448 (2008) 143-147 | en |
dc.identifier.issn | 0304-3940 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18938211 | - |
dc.identifier.uri | http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T0G-4TNWH31-7-9&_cdi=4862&_user=168665&_orig=search&_coverDate=12%2F19%2F2008&_sk=995519998&view=c&wchp=dGLzVtb-zSkzV&md5=e823816718ff5f02a22f1ad460720d10&ie=/sdarticle.pdf | - |
dc.identifier.uri | https://hdl.handle.net/10371/68459 | - |
dc.description.abstract | The acetylcholinesterase inhibitor (AChEI) galantamine is currently used to treat mild to moderate Alzheimer's disease (AD), and it has been suggested to have several neuroprotective effects. To investigate the potential application of this drug to the treatment of Huntington's disease, we examined whether galantamine can reduce the striatal degeneration induced by the mitochondrial toxin, 3-nitropropionic acid (3NP). 3NP (63 mg/kg/day) was delivered to Lewis rats by osmotic pumps for 5 consecutive days, and the rats received intraperitoneal administration of either different concentrations of galantamine (1mg/kg/day or 10 mg/kg/day, twice daily) or vehicle (saline) throughout the experiment. Galantamine attenuated the 3NP-induced neurologic deficits on days 2-5. Galantamine-treated rats showed smaller striatal lesion volumes measured by Nissl staining and lower numbers of TUNEL(+) apoptotic cells when compared to the vehicle-treated rats. Galantamine failed to reduce the striatal lesion volume when co-administered with mecamylamine, a nicotinic acetylcholine receptor antagonist. Our data indicate that galantamine can attenuate neurodegeneration in a Huntington's disease model by modulating nAChR. | en |
dc.description.sponsorship | This study was supported by a grant of Systemic Application
of Research Basis on Rare Diseases Project, Research Center for Rare Diseases, Ministry of Health & Welfare, Republic of Korea (A080588). | en |
dc.language.iso | en | en |
dc.publisher | Elsevier | en |
dc.subject | Analysis of Variance | en |
dc.subject | Animals | en |
dc.subject | Corpus Striatum/drug effects/pathology | en |
dc.subject | Disease Models, Animal | en |
dc.subject | Dose-Response Relationship, Drug | en |
dc.subject | Galantamine/*therapeutic use | en |
dc.subject | Huntington Disease/chemically induced/*complications | en |
dc.subject | In Situ Nick-End Labeling/methods | en |
dc.subject | Male | en |
dc.subject | Nerve Degeneration/*drug therapy/etiology/*pathology | en |
dc.subject | Neurologic Examination | en |
dc.subject | Nitro Compounds | en |
dc.subject | Nootropic Agents/*therapeutic use | en |
dc.subject | Propionic Acids | en |
dc.subject | Rats | en |
dc.subject | Rats, Inbred Lew | en |
dc.subject | Statistics, Nonparametric | en |
dc.title | Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 박정은 | - |
dc.contributor.AlternativeAuthor | 이순태 | - |
dc.contributor.AlternativeAuthor | 임우석 | - |
dc.contributor.AlternativeAuthor | 주건 | - |
dc.contributor.AlternativeAuthor | 김만호 | - |
dc.identifier.doi | 10.1016/j.neulet.2008.10.020 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.